A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: systemic therapy-naive versus -experienced patients

Supplementary Figure 1. The transition of eczema area and severity index (EASI) at four anatomical sites in patients with atopic dermatitis treated with upadacitinib 15 mg or 30 mg. EASI scores on head and neck, trunk, upper limbs, or lower limbs are shown. Data are mean ± standard deviation for systemic therapy-naive patients (blue) and systemic therapy-experienced patients (orange) during the 96-week treatment. **p < 0.01 versus week 0 in systemic therapy-naive patients; †p < 0.05, ††p < 0.01 versus week 0 in systemic therapy-experienced patients, by repeated measures analysis of variance with Bonferroni’ s post hoc test.

Supplementary Figure 2. The transition of atopic dermatitis control tool (ADCT) in patients with atopic dermatitis treated with upadacitinib 15 mg or 30 mg. Data are mean ± standard deviation for systemic therapy-naive patients (blue) and systemic therapy-experienced patients (orange) during the 96-week treatmen. **p < 0.01 versus week 0 in systemic therapy-naive patients; †p < 0.05, ††p < 0.01 versus week 0 in systemic therapy-experienced patients, by repeated measures analysis of variance with Bonferroni’ s post hoc test.

Supplementary Figure 3. Achievement rates of eczema area and severity index (EASI) 75, EASI 90, and EASI 100 in patients with atopic dermatitis treated with upadacitinib 15 mg or 30 mg. Achievement rates of EASI 75, EASI 90, or EASI 100 are shown for systemic therapy-naive patients (blue) and systemic therapy-experienced patients (orange) during the 96-week treatment.

Supplementary Figure 4. Achievement rates of peak pruritus-numerical rating scale (PP-NRS) 4, and atopic dermatitis control tool (ADCT) 7 in patients with atopic dermatitis treated with upadacitinib 15 mg or 30 mg. Achievement rates of PP-NRS 4 and ADCT 7 are shown for systemic therapy-naive patients (blue) and systemic therapy-experienced patients (orange) during the 96-week treatment.

Supplementary Figure 5. The transition of laboratory indexes in patients with atopic dermatitis treated with upadacitinib 15 mg or 30 mg. Values of immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), or total eosinophil count (TEC) are shown as medians for systemic therapy-naive patients (blue) and systemic therapy-experienced patients (orange) during the 96-week treatment.

补充图1. 特应性皮炎患者接受upadacitinib 15 mg或30 mg治疗后，四个解剖部位的湿疹面积及严重程度指数（eczema area and severity index, EASI）变化。展示了头颈部、躯干、上肢或下肢的EASI评分。数据为未接受过系统治疗的患者（蓝色）和接受过系统治疗的患者（橙色）在96周治疗期间的平均值±标准差。**p < 0.01 vs 未接受系统治疗患者的第0周；†p < 0.05，††p < 0.01 vs 接受过系统治疗患者的第0周（采用重复测量方差分析及Bonferroni事后检验）。

补充图2. 特应性皮炎患者接受upadacitinib 15 mg或30 mg治疗后的特应性皮炎控制工具（atopic dermatitis control tool, ADCT）变化。数据为未接受过系统治疗的患者（蓝色）和接受过系统治疗的患者（橙色）在96周治疗期间的平均值±标准差。**p < 0.01 vs 未接受系统治疗患者的第0周；†p < 0.05，††p < 0.01 vs 接受过系统治疗患者的第0周（采用重复测量方差分析及Bonferroni事后检验）。

补充图3. 特应性皮炎患者接受upadacitinib 15 mg或30 mg治疗后，湿疹面积及严重程度指数（EASI）75、EASI 90和EASI 100的达标率。展示了未接受过系统治疗的患者（蓝色）和接受过系统治疗的患者（橙色）在96周治疗期间的EASI 75、EASI 90或EASI 100达标率。

补充图4. 特应性皮炎患者接受upadacitinib 15 mg或30 mg治疗后，峰值瘙痒数字评分量表（peak pruritus-numerical rating scale, PP-NRS）4分及特应性皮炎控制工具（ADCT）7分的达标率。展示了未接受过系统治疗的患者（蓝色）和接受过系统治疗的患者（橙色）在96周治疗期间的PP-NRS 4分和ADCT 7分达标率。

补充图5. 特应性皮炎患者接受upadacitinib 15 mg或30 mg治疗后的实验室指标变化。展示了未接受过系统治疗的患者（蓝色）和接受过系统治疗的患者（橙色）在96周治疗期间的免疫球蛋白E（immunoglobulin E, IgE）、胸腺和活化调节趋化因子（thymus and activation-regulated chemokine, TARC）、乳酸脱氢酶（lactate dehydrogenase, LDH）或总嗜酸性粒细胞计数（total eosinophil count, TEC）的中位数。